Pharmacy Website
    Clinic Website

    Intelligence » HPV » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    HPV vaccine cuts cancer-causing infection

    Monday, June 18, 2018 -- The vaccine has brought about an 86% reduction in cancer-causing infection, a study has found.

    Study to assess immunotherapy combination for HPV-associated head, neck cancers

    Wednesday, June 20, 2018 -- Missak HaigentzResearchers at Atlantic HPV Center at Leonard B. Kahn Head and Neck Cancer Institute will study immunotherapy combinations in a cohort of patients with HPV-associated head and neck cancers.Missak Haigentz, MD, chief of hematology and oncology at Morristown Medical Center and medical director of Atlantic Hematology and Oncology of Atlantic Medical Group at Carol G. Simon Cancer Center, and colleagues will conduct a phase 1b/phase 2a study that will assess an experimental HPV vaccine and treatment with the PD-L1 inhibitor durvalumab (Imfinzi; AstraZeneca).The rationale behind the

    MERCK: FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases

    Wednesday, June 20, 2018 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for GARDASIL ® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), the company’s 9-valent HPV vaccine. Read more..

    Parents Say Cancer Prevention Best Reason for HPV Vaccination

    Thursday, June 21, 2018 -- Findings based on large survey of parents to assess best, worst reasons for vaccination